Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May;39(5):1010428317698370.
doi: 10.1177/1010428317698370.

Fibroblast Growth Factor Receptors in Breast Cancer

Affiliations
Review

Fibroblast Growth Factor Receptors in Breast Cancer

Shuwei Wang et al. Tumour Biol. .

Abstract

Fibroblast growth factor receptors are growth factor receptor tyrosine kinases, exerting their roles in embryogenesis, tissue homeostasis, and development of breast cancer. Recent genetic studies have identified some subtypes of fibroblast growth factor receptors as strong genetic loci associated with breast cancer. In this article, we review the recent epidemiological findings and experiment results of fibroblast growth factor receptors in breast cancer. First, we summarized the structure and physiological function of fibroblast growth factor receptors in humans. Then, we discussed the common genetic variations in fibroblast growth factor receptors that affect breast cancer risk. In addition, we also introduced the potential roles of each fibroblast growth factor receptors isoform in breast cancer. Finally, we explored the potential therapeutics targeting fibroblast growth factor receptors for breast cancer. Based on the biological mechanisms of fibroblast growth factor receptors leading to the pathogenesis in breast cancer, targeting fibroblast growth factor receptors may provide new opportunities for breast cancer therapeutic strategies.

Keywords: Fibroblast growth factor receptor; breast cancer; genetics; therapeutic strategy.

Similar articles

  • Challenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.
    Jain VK, Turner NC. Jain VK, et al. Breast Cancer Res. 2012 Jun 19;14(3):208. doi: 10.1186/bcr3139. Breast Cancer Res. 2012. PMID: 22731805 Free PMC article. Review.
  • FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium.
    Agarwal D, Pineda S, Michailidou K, Herranz J, Pita G, Moreno LT, Alonso MR, Dennis J, Wang Q, Bolla MK, Meyer KB, Menéndez-Rodríguez P, Hardisson D, Mendiola M, González-Neira A, Lindblom A, Margolin S, Swerdlow A, Ashworth A, Orr N, Jones M, Matsuo K, Ito H, Iwata H, Kondo N; kConFab Investigators; Australian Ovarian Cancer Study Group, Hartman M, Hui M, Lim WY, Iau PT, Sawyer E, Tomlinson I, Kerin M, Miller N, Kang D, Choi J-, Park SK, Noh D-, Hopper JL, Schmidt DF, Makalic E, Southey MC, Teo SH, Yip CH, Sivanandan K, Tay W-, Brauch H, Brüning T, Hamann U; GENICA Network, Dunning AM, Shah M, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Schmidt MK, Broeks A, Rosenberg EH, van't Veer LJ, Fasching PA, Renner SP, Ekici AB, Beckmann MW, Shen C-, Hsiung C-, Yu J-, Hou M-, Blot W, Cai Q, Wu AH, Tseng C-, Van Den Berg D, Stram DO, Cox A, Brock IW, Reed MW, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Zheng W, Deming-Halverson S, Shrubsole MJ, Long J, Shu X-, Lu W, Gao Y-, Zhang B, Radice P, Peterlongo P, Manoukian S, Mariette F, Sangrajrang S, McKay J, Couch FJ, Toland AE; TNBCC, Yannoukakos D, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Marme F, Burwinkel B, Guénel P, Truong T, Sanchez M, Mulot C, Bojesen SE, Nordestgaard BG, Flyer H, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Mannermaa A, Kataja V, Kosma V-, Hartikainen JM, Lambrechts D, Yesilyurt BT, Floris G, Leunen K, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Wang X, Olson JE, Vachon C, Purrington K, Giles GG, Severi G, Baglietto L, Haiman CA, Henderson BE, Schumacher F, Marchand LL, Simard J, Dumont M, Goldberg MS, Labréche F, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, Devilee P, Tollenaar RA, Seynaeve C, García-Closas M, Chanock SJ, Lissowska J, Figueroa JD, Czene K, Eriksson M, Humphreys K, Darabi H, Hooning MJ, Kriege M, Collée JM, Tilanus-Linthorst M, Li J, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova N, Dörk T, Hall P, Chenevix-Trench G, Easton DF, Pharroah PD, Arias-Perez JI, Zamora P, Benítez J, Milne RL. Agarwal D, et al. Br J Cancer. 2014 Feb 18;110(4):1088-100. doi: 10.1038/bjc.2013.769. Br J Cancer. 2014. PMID: 24548884 Free PMC article. Clinical Trial.
  • Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F, Bachelot T, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner N, Rugo H, Smith JW, Deudon S, Shi M, Zhang Y, Kay A, Porta DG, Yovine A, Baselga J. André F, et al. Clin Cancer Res. 2013 Jul 1;19(13):3693-702. doi: 10.1158/1078-0432.CCR-13-0190. Epub 2013 May 8. Clin Cancer Res. 2013. PMID: 23658459 Clinical Trial.
  • Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.
    Tarkkonen KM, Nilsson EM, Kähkönen TE, Dey JH, Heikkilä JE, Tuomela JM, Liu Q, Hynes NE, Härkönen PL. Tarkkonen KM, et al. PLoS One. 2012;7(11):e49970. doi: 10.1371/journal.pone.0049970. Epub 2012 Nov 21. PLoS One. 2012. PMID: 23185502 Free PMC article.
  • Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.
    Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Dienstmann R, et al. Ann Oncol. 2014 Mar;25(3):552-63. doi: 10.1093/annonc/mdt419. Epub 2013 Nov 20. Ann Oncol. 2014. PMID: 24265351 Free PMC article. Review.
See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Substances

LinkOut - more resources

Feedback